As Bloomberg reports, at least one analyst thinks that Valeant Pharmaceuticals, always ambitious and eager for a deal, might step in with a competing bid. Valeant is aiming to grow its way into Big Pharma, and a deal this size could really help.
After two proxy battles with Forest Labs and a settlement that warded off a third, longtime rebel investor Carl Icahn finally got his way Tuesday when Actavis announced its $25 billion buyout of the New York City-based company.
Actavis is extending its deal spree with another big buyout. The generics maker has agreed to buy Forest Laboratories for about $25 billion, in a bid to further build up its presence in branded drugs.
Generic drug maker Actavis is unloading some of its manufacturing assets as it digests the big chunk of business it bit off with its Warner Chilcott merger last year. It has reached a deal to unload its piece of a manufacturing plant in China after last week deciding to sell 7 money-losing API plants in Europe.
With a quick one-two, Actavis has bailed out of its China ventures. Just 10 days after its CEO promised to move out of a market he deemed "too risky," the Dublin-based generics maker has sold off its second business there.
Par Pharmaceuticals will pay $490 million to pick up JHP Pharmaceuticals, paying two-and-a-half times what Warburg Pincus laid out for the sterile injectable drug producer last year.
Aurobindo has been looking to expand further in Europe, particularly in the sterile injectables business. With a €30 million ($41 million) deal to buy 7 Actavis active pharmaceutical ingredient facilities across Western Europe, the Indian company will be able to do that in one fell swoop.
Actavis CEO Paul Bisaro says the company has sold a China unit and is in talks to unload another, telling Bloomberg he has decided to retreat from a country that isn't worth all of the effort it requires.
Ask Actavis CEO Paul Bisaro about China and he'll tell you this: It's more trouble than it's worth. As Bloomberg reports, the generics maker is backing away from the Chinese market, despite forecasts of long-term drug-spending growth there.
Pfizer celebrated three birthdays January 1. That's when it officially divided its business into three distinct units, each with its own management and financial reporting--and each with its own prospect of setting off on its own, at least eventually. Analysts are betting that one of those three businesses will be first to go: Already, potential buyers are buzzing.